Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation
Study Details
Study Description
Brief Summary
This study is a prospective randomized trial examining the effect of topically combined antifibrinolytics (Tranexamic acid) with local anesthetics in all electively created surgical wound beds in hand surgery to provide long term pain relief and decrease the use of postoperative narcotics.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
The aim of the study is to provide long term pain relief and decrease the use of postoperative narcotics. All treatments are applied topically to the surgical bed prior to closure of the skin. Each of the drugs used in this study are Food and Drug Administration (FDA) approved and routinely used for pain relief. However, the route of administration of the drugs and addition of tranexamic acid or aminocaproic acid is considered off-label (outside of the FDA-approved indications) and therefore investigational.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Topical lidocaine and bupivacaine alone In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine |
Drug: Lidocaine Hydrochloride with Epinephrine
Topical lidocaine product is FDA approved as an amide local anesthetic in any indication for relief of pain associated with superficial minor surgery and as an adjunct for local infiltration anesthesia. It is frequently used as a standard local anesthetic for surgical procedures.
Each mL contains lidocaine hydrochloride and epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid as a stabilizer.
Total of 5 mLs per open surgical study arm involving lidocaine hydrochloride and epinephrine will be given
Drug: Bupivacaine Hydrochloride with Epinephrine
Topical bupivacaine is FDA approved as indicated for the production of local anesthesia for procedures by infiltration injection. It is frequently used as a standard local anesthetic for surgical procedures.
Each mL contains bupivacaine hydrochloride and 0.005 mg epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid (anhydrous) as stabilizer.
Total of 5 mLs per open surgical study arm involving Bupivacaine Hydrochloride with Epinephrine will be given
|
| Experimental: Topical lidocaine and bupivacaine with thrombin In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin |
Drug: Recombinant Human Thrombin
Topical thrombin is FDA approved as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is not sufficient.
Recombinant human thrombin is available as 5000-unit and 20,000-unit vials of sterile recombinant topical thrombin lyophilized powder for solution. When reconstituted as directed, the final solution contains 1000 units/mL.
For topical application, a total of 10000 units per open surgical study arm involving use of Thrombin will be given
Drug: Lidocaine Hydrochloride with Epinephrine
Topical lidocaine product is FDA approved as an amide local anesthetic in any indication for relief of pain associated with superficial minor surgery and as an adjunct for local infiltration anesthesia. It is frequently used as a standard local anesthetic for surgical procedures.
Each mL contains lidocaine hydrochloride and epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid as a stabilizer.
Total of 5 mLs per open surgical study arm involving lidocaine hydrochloride and epinephrine will be given
Drug: Bupivacaine Hydrochloride with Epinephrine
Topical bupivacaine is FDA approved as indicated for the production of local anesthesia for procedures by infiltration injection. It is frequently used as a standard local anesthetic for surgical procedures.
Each mL contains bupivacaine hydrochloride and 0.005 mg epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid (anhydrous) as stabilizer.
Total of 5 mLs per open surgical study arm involving Bupivacaine Hydrochloride with Epinephrine will be given
|
| Experimental: Topical lidocaine and bupivacaine with thrombin and tranexamic acid In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 500 mg of tranexamic acid |
Drug: Tranexamic acid
FDA-approved usage for intravenous tranexamic acid (TXA) is for heavy menstrual bleeding and short-term prevention in patients with hemophilia.
Total dose of 500 mg (20 mL) total will be given.
Drug: Recombinant Human Thrombin
Topical thrombin is FDA approved as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is not sufficient.
Recombinant human thrombin is available as 5000-unit and 20,000-unit vials of sterile recombinant topical thrombin lyophilized powder for solution. When reconstituted as directed, the final solution contains 1000 units/mL.
For topical application, a total of 10000 units per open surgical study arm involving use of Thrombin will be given
Drug: Lidocaine Hydrochloride with Epinephrine
Topical lidocaine product is FDA approved as an amide local anesthetic in any indication for relief of pain associated with superficial minor surgery and as an adjunct for local infiltration anesthesia. It is frequently used as a standard local anesthetic for surgical procedures.
Each mL contains lidocaine hydrochloride and epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid as a stabilizer.
Total of 5 mLs per open surgical study arm involving lidocaine hydrochloride and epinephrine will be given
Drug: Bupivacaine Hydrochloride with Epinephrine
Topical bupivacaine is FDA approved as indicated for the production of local anesthesia for procedures by infiltration injection. It is frequently used as a standard local anesthetic for surgical procedures.
Each mL contains bupivacaine hydrochloride and 0.005 mg epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid (anhydrous) as stabilizer.
Total of 5 mLs per open surgical study arm involving Bupivacaine Hydrochloride with Epinephrine will be given
|
| Experimental: Topical lidocaine and bupivacaine with thrombin and aminocaproic acid; In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 1000 mg of aminocaproic acid |
Drug: Tranexamic acid
FDA-approved usage for intravenous tranexamic acid (TXA) is for heavy menstrual bleeding and short-term prevention in patients with hemophilia.
Total dose of 500 mg (20 mL) total will be given.
Drug: Aminocaproic acid
FDA notes that aminocaproic acid is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. Aminocaproic acid inhibits both the action of plasminogen activators and to a lesser degree, plasmin activity. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Total of 1000 mg total will be given.
Drug: Recombinant Human Thrombin
Topical thrombin is FDA approved as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is not sufficient.
Recombinant human thrombin is available as 5000-unit and 20,000-unit vials of sterile recombinant topical thrombin lyophilized powder for solution. When reconstituted as directed, the final solution contains 1000 units/mL.
For topical application, a total of 10000 units per open surgical study arm involving use of Thrombin will be given
Drug: Lidocaine Hydrochloride with Epinephrine
Topical lidocaine product is FDA approved as an amide local anesthetic in any indication for relief of pain associated with superficial minor surgery and as an adjunct for local infiltration anesthesia. It is frequently used as a standard local anesthetic for surgical procedures.
Each mL contains lidocaine hydrochloride and epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid as a stabilizer.
Total of 5 mLs per open surgical study arm involving lidocaine hydrochloride and epinephrine will be given
Drug: Bupivacaine Hydrochloride with Epinephrine
Topical bupivacaine is FDA approved as indicated for the production of local anesthesia for procedures by infiltration injection. It is frequently used as a standard local anesthetic for surgical procedures.
Each mL contains bupivacaine hydrochloride and 0.005 mg epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid (anhydrous) as stabilizer.
Total of 5 mLs per open surgical study arm involving Bupivacaine Hydrochloride with Epinephrine will be given
|
Outcome Measures
Primary Outcome Measures
- Change in Postoperative Pain control [Day1 of Surgery until post operative day 14]
Measured by self-reported level of pain recorded in a daily pain diary made by the researchers from the day of the surgery until post-operative day 14. The levels of pain are scored in the following manner: 1-2 no pain, 3-4 mild pain, 5-6 moderate pain, 7-8 severe pain, 9-10 worst pain imaginable.
Secondary Outcome Measures
- Change in the amount of opioid pain medication required postoperatively [Day1 of Surgery until post operative day 14]
Measured by self-reported number of pain pills taken postoperatively until post-operative day 14.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age 18 or older
-
Any patient undergoing elective hand surgery
Exclusion Criteria:
-
Any patient with a traumatic open wound (only surgically created wounds will be included)
-
History of chronic pain
-
History of narcotic addiction
-
History of recreational drug dependency
-
History of psychiatric pathology
-
Allergy to local anesthetics, recombinant human thrombin or tranexamic acid
-
Any patient receiving a supra/infraclavicular block for anesthesia
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | NYU Langone Health | New York | New York | United States | 10016 |
Sponsors and Collaborators
- NYU Langone Health
Investigators
- Principal Investigator: David Chiu, MD, NYU Langone Health
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 20-01420